BioLineRx To Report Fourth Quarter And Year End 2012 Results On March 12, 2013

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that it will release its financial results for the quarter and year ended December 31, 2012 on Tuesday, March 12, 2013, before the U.S. markets open.

The Company will host a conference call on Tuesday, March 12 at 10:00 a.m. EST featuring remarks by Kinneret Savitsky, Ph.D., CEO of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx’s website, www.biolinerx.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-407-2553 from the U.S. or +972-3-918-0610 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com or www.kcsa.com. A dial-in replay of the call will be available until March 15, 2013; please dial 1-877-456-0009 from the U.S. or +972-3-925-5927 internationally.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of six clinical stage candidates: BL-1020 for schizophrenia is currently undergoing a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development, BL-7040 for treating inflammatory bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has completed Phase I. In addition, BioLineRx has eight products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

If you liked this article you might like

BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement

7 Stocks Under $10 to Trade for Big Profits

7 Stocks Under $10 Making Big Moves

BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results

Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation